argenx SE
ARGX877.940USD
-11.550-1.30%
Close 12/12, 16:00（ET）Quotes delayed by 15 min
53.70BMarket Cap
34.64P/E TTM
More Details of argenx SE Company
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
argenx SE Info
Ticker SymbolARGX
Company nameargenx SE
IPO dateJul 10, 2014
CEOvan Hauwermeiren (Tim)
Number of employees1599
Security typeDepository Receipt
Fiscal year-endJul 10
AddressLaarderhoogtweg 25
CityAMSTERDAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code1101 EB
Phone31763030
Websitehttps://www.argenx.com/
Ticker SymbolARGX
IPO dateJul 10, 2014
CEOvan Hauwermeiren (Tim)
Company Executives of argenx SE
Name
Name/Position
Position
Shareholding
Change
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
500.00
--
Mrs. Camilla Sylvest
Mrs. Camilla Sylvest
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Ana Cespedes
Dr. Ana Cespedes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Karen Massey
Ms. Karen Massey
Chief Operating Officer
Chief Operating Officer
--
--
Mrs. Andria Wilk
Mrs. Andria Wilk
Global Head of Quality
Global Head of Quality
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Ms. Malini Moorthy
Ms. Malini Moorthy
General Counsel
General Counsel
--
--
Mr. Peter Ulrichts
Mr. Peter Ulrichts
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Peter K. M. Verhaeghe
Mr. Peter K. M. Verhaeghe
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
500.00
--
Mrs. Camilla Sylvest
Mrs. Camilla Sylvest
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Ana Cespedes
Dr. Ana Cespedes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Karen Massey
Ms. Karen Massey
Chief Operating Officer
Chief Operating Officer
--
--
Mrs. Andria Wilk
Mrs. Andria Wilk
Global Head of Quality
Global Head of Quality
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
1.90B
86.56%
Rest of the World
161.25M
7.36%
Japan
89.39M
4.08%
China
43.52M
1.99%
Netherlands
153.00K
0.01%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
8.96%
T. Rowe Price Associates, Inc.
4.60%
Janus Henderson Investors
4.21%
Artisan Partners Limited Partnership
3.57%
Capital World Investors
3.20%
Other
75.46%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
8.96%
T. Rowe Price Associates, Inc.
4.60%
Janus Henderson Investors
4.21%
Artisan Partners Limited Partnership
3.57%
Capital World Investors
3.20%
Other
75.46%
Shareholder Types
Shareholders
Proportion
Investment Advisor
27.69%
Investment Advisor/Hedge Fund
16.94%
Hedge Fund
4.43%
Research Firm
1.11%
Pension Fund
0.38%
Private Equity
0.31%
Bank and Trust
0.10%
Family Office
0.01%
Other
49.03%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
855
32.28M
58.19%
+72.85K
2025Q3
891
32.22M
58.55%
-544.28K
2025Q2
847
32.65M
61.10%
-1.53M
2025Q1
821
34.16M
62.26%
-3.81M
2024Q4
770
34.96M
63.31%
-1.04M
2024Q3
718
36.05M
63.46%
+556.56K
2024Q2
690
35.13M
62.09%
+253.45K
2024Q1
672
34.89M
59.82%
-632.92K
2023Q4
654
33.46M
57.06%
+708.68K
2023Q3
609
32.76M
55.78%
+1.52M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
5.21M
8.52%
-251.10K
-4.59%
Jun 30, 2025
T. Rowe Price Associates, Inc.
4.09M
6.69%
-498.08K
-10.85%
Jun 30, 2025
Janus Henderson Investors
2.57M
4.19%
+422.32K
+19.71%
Jun 30, 2025
Artisan Partners Limited Partnership
2.35M
3.84%
-436.11K
-15.65%
Jun 30, 2025
Capital World Investors
1.95M
3.19%
+13.09K
+0.68%
Jun 30, 2025
Avoro Capital Advisors LLC
1.18M
1.92%
-60.18K
-4.87%
Jun 30, 2025
T. Rowe Price International Ltd
887.87K
1.45%
+93.47K
+11.77%
Jun 30, 2025
ClearBridge Investments, LLC
772.87K
1.26%
+108.50K
+16.33%
Jun 30, 2025
Wellington Management Company, LLP
405.33K
0.66%
-871.00
-0.21%
Jun 30, 2025
Citadel Advisors LLC
865.97K
1.42%
+314.03K
+56.90%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
VanEck Biotech ETF
5.04%
iShares Neuroscience and Healthcare ETF
4.22%
Goldman Sachs Future Health Care Equity ETF
3.92%
First Trust NYSE Arca Biotechnology Index Fund
3.45%
iShares Biotechnology ETF
3.12%
PGIM Jennison International Opportunities ETF
2.55%
ProShares Ultra Nasdaq Biotechnology
2.46%
Invesco Nasdaq Biotechnology ETF
2.44%
American Century Mid Cap Growth Impact ETF
1.63%
Invesco NASDAQ Next Gen 100 ETF
1.37%
View more
VanEck Biotech ETF
Proportion5.04%
iShares Neuroscience and Healthcare ETF
Proportion4.22%
Goldman Sachs Future Health Care Equity ETF
Proportion3.92%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.45%
iShares Biotechnology ETF
Proportion3.12%
PGIM Jennison International Opportunities ETF
Proportion2.55%
ProShares Ultra Nasdaq Biotechnology
Proportion2.46%
Invesco Nasdaq Biotechnology ETF
Proportion2.44%
American Century Mid Cap Growth Impact ETF
Proportion1.63%
Invesco NASDAQ Next Gen 100 ETF
Proportion1.37%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of argenx SE?
The top five shareholders of argenx SE are:
Fidelity Management & Research Company LLC holds 5.21M shares, accounting for 8.52% of the total shares.
T. Rowe Price Associates, Inc. holds 4.09M shares, accounting for 6.69% of the total shares.
Janus Henderson Investors holds 2.57M shares, accounting for 4.19% of the total shares.
Artisan Partners Limited Partnership holds 2.35M shares, accounting for 3.84% of the total shares.
Capital World Investors holds 1.95M shares, accounting for 3.19% of the total shares.
Fidelity Management & Research Company LLC holds 5.21M shares, accounting for 8.52% of the total shares.
T. Rowe Price Associates, Inc. holds 4.09M shares, accounting for 6.69% of the total shares.
Janus Henderson Investors holds 2.57M shares, accounting for 4.19% of the total shares.
Artisan Partners Limited Partnership holds 2.35M shares, accounting for 3.84% of the total shares.
Capital World Investors holds 1.95M shares, accounting for 3.19% of the total shares.
What are the top three shareholder types of argenx SE?
The top three shareholder types of argenx SE are:
Fidelity Management & Research Company LLC
T. Rowe Price Associates, Inc.
Janus Henderson Investors
Fidelity Management & Research Company LLC
T. Rowe Price Associates, Inc.
Janus Henderson Investors
How many institutions hold shares of argenx SE (ARGX)?
As of 2025Q4, 855 institutions hold shares of argenx SE, with a combined market value of approximately 32.28M, accounting for 58.19% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.36%.
What is the biggest source of revenue for argenx SE?
In FY2024, the -- business generated the highest revenue for argenx SE, amounting to -- and accounting for --% of total revenue.
